Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Sees Significant Increase in Short Interest

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) was the recipient of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 32,118 shares, an increase of 112.6% from the January 15th total of 15,105 shares. Based on an average daily volume of 31,647 shares, the short-interest ratio is presently 1.0 days. Currently, 0.3% of the company’s stock are sold short. Currently, 0.3% of the company’s stock are sold short. Based on an average daily volume of 31,647 shares, the short-interest ratio is presently 1.0 days.

Analysts Set New Price Targets

RADX has been the topic of several recent analyst reports. B. Riley Financial reaffirmed a “buy” rating and set a $16.00 target price (up from $13.00) on shares of Radiopharm Theranostics in a research report on Tuesday, December 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Radiopharm Theranostics in a report on Thursday, January 22nd. Finally, Wall Street Zen cut shares of Radiopharm Theranostics to a “strong sell” rating in a research note on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Radiopharm Theranostics currently has an average rating of “Buy” and a consensus target price of $15.33.

Radiopharm Theranostics Price Performance

Shares of RADX stock opened at $4.90 on Friday. Radiopharm Theranostics has a twelve month low of $3.50 and a twelve month high of $16.25. The company’s 50-day moving average price is $5.15 and its 200-day moving average price is $5.39.

Institutional Trading of Radiopharm Theranostics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. acquired a new position in Radiopharm Theranostics in the second quarter valued at approximately $37,000. Marex Group plc acquired a new position in shares of Radiopharm Theranostics in the 4th quarter valued at $54,000. Finally, Jane Street Group LLC acquired a new stake in shares of Radiopharm Theranostics during the 4th quarter worth about $76,000.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.